Login to Your Account



Vical Abandons Several Studies, Including Phase III Of Allovectin-7

By Brady Huggett


Thursday, September 19, 2002
Employing a slash-and-burn technique to streamline its pipeline, Vical Inc. said it is not completing its Phase III low-dose trial of Allovectin-7 in metastatic melanoma due to the improbability of it achieving desired endpoints, is closing a Phase II trial of Allovectin-7 for early stage head and neck cancer, and would no longer develop Leuvectin for prostate or kidney cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription